- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Respiratory epithelium.
Displaying page 1 of 1.
EudraCT Number: 2019-003768-31 | Sponsor Protocol Number: NNF18OC0052256 | Start Date*: 2019-12-05 |
Sponsor Name:Lungemedicinsk Forskningsenhed | ||
Full Title: Effects of azithromycin treatment on anti-viral immunity in patients with asthma and COPD. | ||
Medical condition: COPD and asthma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000361-78 | Sponsor Protocol Number: HTA-HUR-01 | Start Date*: 2020-12-01 |
Sponsor Name:HOLOSTEM TERAPIE AVANZATE S.R.L. | ||
Full Title: PROSPECTIVE, OPEN-LABEL, UNCONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF AUTOLOGOUS CULTURED ORAL MUCOSA GRAFTS FOR URETHRAL RECONSTRUCTION IN PATIENTS DUE TO HYPOSPADIAS TREATMENT... | ||
Medical condition: Urethral reconstruction in patients due to hypospadias treatment failure. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001563-12 | Sponsor Protocol Number: 20142017 | Start Date*: 2015-02-16 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Efficacy of Single inhaler Maintenance And Reliever Therapy (SMART) with Spiromax® budesonide/formoterol versus fixed dose treatment with Diskus® fluticasone/salmeterol in COPD | ||
Medical condition: Chronic obstructive pulmonary disease (COPD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004344-30 | Sponsor Protocol Number: Moli1901-010A | Start Date*: 2005-10-31 |
Sponsor Name:AOP Orphan Pharmaceuticals AG | ||
Full Title: An Evaluation of the Safety and Tolerability of Multiple Dose Regimens of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis and Stable Lung Disease | ||
Medical condition: Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10,000 children. In cystic fibrosis chloride transport across the respiratory epithelium... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000275-14 | Sponsor Protocol Number: GB29260 | Start Date*: 2014-08-07 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A Phase II, randomized, double-blind, placebo-controlled bronchoscopy study to evaluate the effects of Lebrikizumab on airway eosinophilic inflammation in patients with uncontrolled asthma on inhal... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) IE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003581-25 | Sponsor Protocol Number: APA-III | Start Date*: 2015-05-26 |
Sponsor Name:University Hospital Tuebingen | ||
Full Title: Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - Randomised, double-blind, placebo-controlled cohort trial | ||
Medical condition: Amitriptyline reduces ceramide concentrations in bronchial epithelial cells and reduces cell death and reduces the deposition of DNA on the respiratory epithelium. This reduction promotes the elimi... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-023355-29 | Sponsor Protocol Number: PO1425 | Start Date*: 2011-05-18 | |||||||||||
Sponsor Name:Papworth Hospital NHS Foundation Trust | |||||||||||||
Full Title: Tyrosine kinase Inhibitors in DysplAsia of Lung epithelium Study 1 | |||||||||||||
Medical condition: High grade dysplasia of the bronchoepithelium | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006693-24 | Sponsor Protocol Number: Moli1901-010B | Start Date*: 2007-05-09 | |||||||||||
Sponsor Name:AOP Orphan Pharmaceuticals AG | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis | |||||||||||||
Medical condition: Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10.000 children. In cystic fibrosis chloride transport across the respiratory epithelium... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) CZ (Completed) FR (Completed) DE (Completed) HU (Completed) SE (Completed) ES (Completed) PL (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003343-29 | Sponsor Protocol Number: RG_12-179 | Start Date*: 2013-01-18 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Simvastatin as adjuvant therapy to correct neutrophil dysfunction in older pneumonia patients - a randomised double blind placebo controlled trial | |||||||||||||
Medical condition: Acute episodes of Pneumonia and sepsis in older adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005542-56 | Sponsor Protocol Number: ESR-15-10870 | Start Date*: 2016-04-29 | |||||||||||
Sponsor Name:Copenhagen University Hospital Bispebjerg | |||||||||||||
Full Title: Effects of anti-TSLP on airway hyperresponsiveness and mast cell phenotype in asthma - A randomized double-blind, placebo-controlled trial of MEDI9929 The UPSTREAM study | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003391-13 | Sponsor Protocol Number: D3250C00059 | Start Date*: 2019-09-03 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asth... | ||||||||||||||||||
Medical condition: Severe eosinophilic asthma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001975-40 | Sponsor Protocol Number: 1219.5 | Start Date*: 2007-01-04 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effects of a 4-week treatment of 15 mg b.i.d BIBW 2948 BS (inhalation powder, hard capsule for HandiHaler®) on e... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) patients with symptoms associated with chronic bronchitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000582-13 | Sponsor Protocol Number: RO-2455-402-RD | Start Date*: 2012-03-05 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd. | |||||||||||||
Full Title: A 16-week, randomized, placebo-controlled, double blind, and parallel group trial to assess the anti-inflammatory effects of Roflumilast in chronic obstructive pulmonary disease The ROBERT study ... | |||||||||||||
Medical condition: severe chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) SE (Completed) PL (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020763-20 | Sponsor Protocol Number: 10072DMcA-CS | Start Date*: 2010-10-04 |
Sponsor Name:National University of Ireland, Galway | ||
Full Title: Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP 2) | ||
Medical condition: Acute lung injury | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
